Editing Ciprofloxacin (section)

===Other===
The other black box warning is that ciprofloxacin should not be used in people with [[myasthenia gravis]] due to possible exacerbation of muscle weakness which may lead to breathing problems resulting in death or ventilator support. Fluoroquinolones are known to block neuromuscular transmission.<ref name="Cipro FDA label" /> There are concerns that fluoroquinolones including ciprofloxacin can affect cartilage in young children.<ref name="Cipro FDA label" />

''[[Clostridioides difficile (bacteria)|Clostridioides difficile]]''-associated diarrhea is a serious adverse effect of ciprofloxacin and other fluoroquinolones; it is unclear whether the risk is higher than with other broad-spectrum antibiotics.<ref name="pmid18067688">{{cite journal |vauthors = Deshpande A, Pant C, Jain A, Fraser TG, Rolston DD |title = Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence |journal = Current Medical Research and Opinion |volume = 24 |issue = 2 |pages = 329–33 |date = February 2008 |pmid = 18067688 |doi = 10.1185/030079908X253735 |s2cid = 280563}}</ref>

A wide range of rare but potentially fatal adverse effects reported to the US FDA or the subject of case reports includes [[aortic dissection]],<ref>{{cite web |url=https://www.fda.gov/Drugs/DrugSafety/ucm628753.htm |title=Drug Safety and Availability – FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients |publisher=U.S. [[Food and Drug Administration]] (FDA) |access-date=4 January 2019}}</ref> [[toxic epidermal necrolysis]], [[Stevens–Johnson syndrome]], low blood pressure, allergic pneumonitis, bone marrow suppression, hepatitis or liver failure, and sensitivity to light.<ref name="Cipro FDA label" /><ref name="pmid24352180">{{cite journal |vauthors=Alshammari TM, Larrat EP, Morrill HJ, Caffrey AR, Quilliam BJ, LaPlante KL |title=Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study |journal=American Journal of Health-System Pharmacy |volume=71 |issue=1 |pages=37–43 |date=January 2014 |pmid=24352180 |doi=10.2146/ajhp130165}}</ref> The medication should be discontinued if a rash, jaundice, or other sign of hypersensitivity occurs.<ref name="Cipro FDA label" />

Children and the elderly are at a much greater risk of experiencing adverse reactions.<ref name="autogenerated1403">{{cite journal |vauthors = Iannini PB |title = The safety profile of moxifloxacin and other fluoroquinolones in special patient populations |journal = Current Medical Research and Opinion |volume = 23 |issue = 6 |pages = 1403–13 |date = June 2007 |pmid = 17559736 |doi = 10.1185/030079907X188099 |s2cid = 34091286 }}</ref><ref>{{cite journal |vauthors = Owens RC, Ambrose PG |title = Antimicrobial safety: focus on fluoroquinolones |journal = Clinical Infectious Diseases |volume = 41 |pages = S144–57 |date = July 2005 |issue = Suppl 2 |pmid = 15942881 |doi = 10.1086/428055 |doi-access = free | title-link = doi }}</ref>